Featured Commentaries
Amylyx’s Decision to Remove Relyvrio from the Market
This perspective was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news.
04/05/2024Global HTA Collaboration on Disease Pathways
NICE announced a collaboration with ICER, CADTH, and ZIN (also known as the National Healthcare Institute in the Netherlands) to share learnings about the development of economic models at the disease level (rather than product level).
03/01/2024ICER’s Sarah Emond at the 2024 J.P. Morgan Healthcare Conference
For those of you who made the annual trek to J.P. Morgan, we hope you enjoyed your time. Among the speakers was ICER’s President and CEO, Sarah Emond, who spoke about GLP-1 therapies and the obesity treatment landscape.
01/19/2024